Get started
Author

Bradley Lufkin

Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure
2021 · Hector S Izurieta, Xiyuan Wu, et al. · Clinical Infectious Diseases · 145
PDF
Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries
2021 · Ravi Goud, Bradley Lufkin, et al. · JAMA Internal Medicine · 86
Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019–2020
2022 · Keran Moll, Bradley Lufkin, et al. · Vaccine · 40
Surveillance for Guillain-Barré syndrome after 2015–2016 and 2016–2017 influenza vaccination of Medicare beneficiaries
2019 · Deepa P. Arya, Maria A. Said, et al. · Vaccine · 30
Guillain-Barré Syndrome After High-Dose Influenza Vaccine Administration in the United States, 2018–2019 Season
2020 · Silvia Perez-Vilar, Mao Hu, et al. · The Journal of Infectious Diseases · 29
PDF
Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older
2022 · Hui-Lee Wong, Ellen Tworkoski, et al. · Vaccine · 28
PDF
Surveillance for Guillain-Barré syndrome after influenza vaccination among U.S. Medicare beneficiaries during the 2017–2018 season
2019 · Silvia Perez-Vilar, Michael Wernecke, et al. · Vaccine · 21
Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing COVID-19–Related Thromboembolic Events Among Medicare Enrollees Aged ≥65 Years and Those with End Stage Renal Disease — United States, September 2022–March 2023
2024 · Amanda B. Payne, Shannon Novosad, et al. · MMWR Morbidity and Mortality Weekly Report · 13
PDF
Effectiveness of 2023–2024 COVID-19 vaccines against COVID-19–associated hospitalizations among adults aged ≥18 years with end stage kidney disease — United States, September 2023–April 2024
2025 · Amanda B. Payne, Shannon Novosad, et al. · Vaccine · 8
Trends in Erythropoiesis‐stimulating agent use and blood transfusions for chemotherapy‐induced anemia throughout FDA 's risk evaluation and mitigation strategy lifecycle
2021 · Amarilys Vega, Rongmei Zhang, et al. · Pharmacoepidemiology and Drug Safety · 3
Effectiveness of Bivalent mRNA COVID-19 Vaccine Among Adults With Kidney Failure Receiving Dialysis: A Cohort Study From the Centers for Medicare and Medicaid Services
2025 · Amanda B. Payne, Shannon Novosad, et al. · American Journal of Kidney Diseases · 2
Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Pneumonia Hospitalization Among Medicare Beneficiaries Aged ≥65 Years in Long-Term Care
2025 · Lindsay Zielinski, Kristin Andrejko, et al. · The Journal of Infectious Diseases · 2
Incidence rates of thrombosis with thrombocytopenia syndrome (TTS) among adults in United States commercial and Medicare claims databases, 2017–2020
2024 · Patricia C. Lloyd, Bradley Lufkin, et al. · Vaccine · 1
Letter to the Editor in Response to Zhao et al
2025 · Lindsay Zielinski, Kristin Andrejko, et al. · The Journal of Infectious Diseases
P-2049. Interim Estimates of Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Outcomes Among Medicare Enrollees with End Stage Renal Disease — United States, September – December 2023
2025 · Amanda B Payne, Shannon Novosad, et al. · Open Forum Infectious Diseases
1173. Risk of Pneumococcal Disease and Rate of Pneumococcal Vaccination Among Medicare Beneficiaries Aged 65 Years and Older Residing in Long-Term Care Facilities — United States, September 1, 2014 – December 31, 2019
2023 · Miwako Kobyashi, Kristin Andrejko, et al. · Open Forum Infectious Diseases
PDF
Disparities in erythropoiesis-stimulating agent use after changes in medicare reimbursement and implementation of a risk evaluation and mitigation strategy
2022 · Hui-Lee Wong, Rongmei Zhang, et al. · Drugs & Therapy Perspectives
Works count: 17
Citation count: 408
H-index: 8
I10-index: 8
Year
Topic
Type